ÂÜÀòÂÒÂ×

Julie Lucas is a Principal Scientist at MRIGlobal since January 2010, focusing on applied infectious disease research with an emphasis on biodefense and emerging pathogens, and possesses expertise in biochemistry, pharmacology, immunology, and microbiology. Prior experience includes serving as a Scientist at MannKind Corporation from 2007 to 2009, where drug discovery efforts targeted small molecule inhibitors for multiple myeloma, and as a Postdoctoral Research Scientist at Bayer HealthCare from 2005 to 2007, investigating HDAC inhibitors' anti-inflammatory effects in T cells. Julie's academic background includes a Ph.D. in Pharmaceutical Sciences from the University of California, San Francisco, obtained in 2004, and a B.S. in Pharmacology from UC Santa Barbara in 1999.